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Abstract
The role of inflammation in Alzheimer's disease (AD) has been controversial since its first
consideration. As with most instances of neuroinflammation, the possibility must be considered
that activation of glia and cytokine network s  i n  A D  a r i s e s  m e r e l y  a s  a  r e a c t i o n  t o
neurodegeneration. Active, healthy neurons produce signals that suppress inflammatory events,
and dying neurons activate phagocytic responses in microglia at the very least. But simultaneous
with the arrival of a more complex view of microglia, evidence that inflammation plays a causal or
exacerbating role in AD etiology has been boosted by genetic, physiological, and epidemiological
studies. In the end, it may be that the semantics of "inflammation" and glial "activation" must be
regarded as too simplistic for the advancement of our understanding in this regard. It is clear that
elaboration of the entire repertoire of activated microglia – a phenomenon that may be termed
"malactivation" – must be prevented for healthy brain structure and function. Nevertheless, recent
studies have suggested that phagocytosis of Aβ by microglia plays an important role in clearance of
amyloid plaques, a process boosted by immunization paradigms. To the extent that this clearance
might produce clinical improvements (still an open question), this relationship thus obligates a more
nuanced consideration of the factors that indicate and control the various activities of microglia and
other components of neuroinflammation.
Introduction
Alzheimer's disease (AD) is a progressive degeneration of
neural structure and function that arises in the cerebral
cortex. Behaviorally, affected individuals usually present
with semantic difficulty, followed by a deficiency in epi-
sodic memory, spatial disorientation, sleep disturbances,
depression, agitation, loss of longer memories, general
difficulty with the activities of daily living, and eventually,
death. Neuropathological findings include a relatively
high number of extracellular deposits of the amyloid β-
peptide (Aβ), argyrophillic cytoskeletal aggregates in neu-
rons, accumulation of α-synuclein, loss of synapses, loss
of cholinergic and adrenergic fibers, loss of pyramidal
neurons, and cerebral amyloid angiopathy (CAA) – depo-
sition of Aβ around blood vessels.
Most of the AD correlates above have been connected in
some way to inflammation. For instance, the plaques –
comprised primarily of aggregated amyloid β-peptide
(Aβ) – are inundated with microglia that show profiles of
morphology and gene expression consistent with inflam-
mation. Indeed, if one characterizes any activity by micro-
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glia as a sign of "neuroinflammation," it can be said that
inflammatory responses have been evident in AD for at
least 40 years [1]. But, it was not until the late 1980s that
investigators were willing to express the hypothesis that
inflammatory events were causal or otherwise contribut-
ing to the progression of the disease. Recognition of the
powerful impact of a cytokine like interleukin-1 (IL-1),
elevated in AD microglia, permitted such speculation [2].
Similarly, research accrued showing that primary inflam-
mation could lead to many of the aberrations found in
AD, fueling the consideration that inflammatory events
were seminal [3-5]. Many of the individual molecules pro-
duced by activated microglia and astrocytes are condi-
tional neurotoxins: hydrogen peroxide, glutamate and
other agonists of glutamate receptors, complement com-
ponents, prostanoids. (Nitric oxide from inducible nitric
oxide synthase, produced abundantly in rodent glia, may
be less important in human tissues.) Retrospective epide-
miological studies showed protection against AD – either
in age of onset or rate of progression – by nonsteroidal
antiinflammatory drugs (NSAIDs); such correlations have
now been born out in a prospective study [6]. Perhaps
most compelling, polymorphisms in the genes for proin-
flammatory cytokines are indicative of risk for AD [7].
Despite these indications, there are reasons to believe that
the changes observed in glia and inflammatory cytokines
constitute a compensatory response in AD. Indeed, some
investigators have been reluctant to apply the term
"inflammation" to the constellation of events related to
AD pathology. Some of the cytokines and other gene
products expressed in peripheral sites of inflammation are
present in the AD brain, but there is no apparent vasodi-
lation or extravasation of neutrophils. In general, there
seems to be less of the molecular and cellular behavior
that is responsible for bystander tissue damage in periph-
eral inflammation. This journal was founded partially out
of recognition that "neuroinflammation" is distinct. In
essence, the concept reflects a compromise befitting the
difficult line that must be maintained between effective
cell-mediated immune responses and damage to the pre-
cious components of the CNS. Microglia elevate their
expression of neurotrophic factors under many of the
same conditions in which they show inflammation-
related responses such as phagocytosis, retraction of proc-
esses, release of excitotoxins, and production of IL-1β and
IL-6 and tumor necrosis factor [8]; in fact, the latter
cytokines can have neurotrophic effects themselves [9,10].
Astrocytes deposit proteoglycans around the Aβ deposits
destined to become plaques [11], perhaps sequestering
this neurotoxic peptide from doing its harm. Even the
apparent benefits of NSAIDs can be parsed from their pre-
sumed mechanism of inhibiting cyclooxygenase-2
[12,13](and references therein).
Discussion
Recent experiments with anti-Aβ immunization have
highlighted another beneficial effect of "activated" micro-
glia: removal of Aβ. It has long been recognized that
microglia can efficiently phagocytose and at least partially
degrade Aβ both in vitro and in vivo. But the persistence
of amyloid plaques suggests that microglia are stymied in
this regard during the development of AD or in the depo-
sition of Aβ in mice transgenically engineered to produce
large amounts of the peptide. Introduction of antibodies
recognizing Aβ, either by active vaccination or by passive
immunization (injection of antibodies, typically mono-
clonal), results in removal of some Aβ deposits and/or
prevention of their formation. Although the phenome-
non has been studied most rigorously in the transgenic
mouse models, similar clearance of parenchymal plaques
seems to have occurred in two human subjects that partic-
ipated in an Aβ-vaccine trial [14,15]. And microglia
appear to contribute; Aβ can be readily detected in micro-
glia of immunized mice [16] and was also abundant in
some microglia and related syncitia in the AD trial sub-
jects [14,15]. However, the only reason we are privy to the
effects of the vaccination paradigm in humans is because
these two individuals died after complications of menin-
geal encephalitis – rampant cranial inflammation brought
on by the immunization. This iatrogenic event occurred in
about five percent of the human subjects vaccinated
against Aβ, prompting discontinuation. One interesting
finding from both autopsies is that while parenchymal Aβ
deposits were substantially lower than to be expected in
AD victims, both individuals had relatively high levels of
vascular deposition. This CAA was accompanied by
microhemorrhage in at least one of the subjects [15], con-
sistent with the majority of advanced cases of CAA [17].
Wilcock et al. [18] have now produced evidence that the
appearance of CAA after immunization may represent an
actual increase in this parameter triggered by anti-Aβ anti-
bodies. Furthermore, the investigators also found that the
CAA was accompanied by an increase in hemorrhages –
similar to a previous report [19] – and a vascular accumu-
lation of CD45+ cells presumed to be microglia. The exper-
imental paradigm was one of passive immunization of
transgenic mice at nearly two years of age, old enough to
have accumulated substantial Aβ deposits. Consistent
with expectations, injection of anti-Aβ antibody dimin-
ished deposits in the parenchyma, even those that were
mature enough to stain with Congo red. However, vascu-
lar deposition of Congo-red staining was elevated by
approximately four-fold in the anti-Aβ-treated animals.
Pfeiffer et al. found similar results in another transgenic
line [19]. Further, Wilcock et al. now show that the
regional accumulation of vascular amyloid was accompa-
nied by an elevated index of hemorrhages and a congrega-
tion of CD45+ cells, presumed to be microglia [18]. GivenJournal of Neuroinflammation 2005, 2:2 http://www.jneuroinflammation.com/content/2/1/2
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that stromal microglia show increased signs of activity
and contain Aβ after passive Aβ immunization [20], one
interpretation is that the immunization-induced shift in
amyloid from the parenchyma to the vasculature is medi-
ated by phagocytic microglia attempting to discard the Aβ
into the bloodstream. Such a phenomenon is tenuously
supported by the analogous transport of pyknotic neuro-
nal nuclei to the vasculature by microglia, observed in 3-
D time-lapse videos by Dailey and coworkers [21]. In
those images, microglia are occasionally seen to transfer
the nuclei to another cell, conceivably a perivascular mac-
rophage or dendritic cell. Thus, it is not clear whether the
CD45+  cells observed by Wilcock and coworkers are
microglia or another cell type. It is also unclear whether
the accumulation of amyloid and inflammatory cells at
the blood vessels represents an arrested state in Aβ clear-
ance or simply a bottleneck in the transport, one that
would eventually yield to complete removal of the pep-
tide. However, the appearance of CAA in the human sub-
jects that suffered from acute encephalitis suggests that the
vascular accumulation is an untoward event, created or
facilitated by inflammation. Another vascular irregularity
caused by Aβ has been linked to inflammatory events in
both transgenic mice and isolated human blood vessels
[22].
The apparent contributions of inflammatory mechanisms
to both Aβ clearance and vascular pathology illustrate a
somewhat unique example of microglial ambivalence.
While many had argued that microglial "activation" by Aβ
was at least partially responsible for AD-associated degen-
eration, others had pointed to microglial phagocytosis as
a desirable consequence of activation. For the purposes of
discussion, the term "malactivation" will be applied here
to microglial activation which produces neurodegenera-
tion. One obvious question is whether there might be a
mode of "activation" that permits phagocytosis while lim-
iting malactivation. In fact, stimulation of Fc receptors –
the antibody receptors that initiate a good deal of anti-
body-triggered phagocytosis – can inhibit cytotoxicity in
macrophages [23]. Similarly, phagocytosis of apoptotic
cells inhibits macrophage expression of proinflammatory
cytokines like IL-1, IL-8, tumor necrosis factor, and several
prostanoids through stimulation of a phosphatidylserine
receptor [24]. Evidence indicates that malactivation
involves the production of reactive oxygen species like
superoxide and peroxide, nitric oxide, and excitotoxins
(glutamate, quinolinate, and D-serine). If these criteria are
germane, malactivation certainly can be suppressed by
specific cytokines, such as transforming growth factor β
(TGFβ) [25]. Although TGFβ has often been characterized
broadly as "anti-inflammatory," it does not inhibit the
phagocytic activity of microglia in a setting where another
"anti-inflammatory" cytokine (IL-4) does [26]. Interest-
ingly, TGFβ1 transgenesis promotes the same apparent
shift of Aβ from parenchyma to vessel that is observed
after Aβ immunization [27].
Conclusions
While some have argued that CAA is of little consequence
in AD [28], the elaboration of the deposition that appears
to occur under conditions of "beneficial inflammation" is
on par with that seen in hereditary cerebral hemorrhage
with angiopathy-Dutch type and is certainly a risk factor
for devastating levels of hemorrhage. If such a response
reflects a broad-acting realignment of cytokine profiles
contingent upon immunization, it behooves careful con-
sideration (and extensive animal testing) for any strategy
for antibody-mediated reduction of Aβ in the AD brain.
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